| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IL3R; CD123; IL3RX; IL3RY; IL3RAY; hIL-3Ra |
| Entrez GeneID | 3563; |
| WB Predicted band size | 43kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthetic peptide of human interleukin 3 receptor, alpha (low affinity) |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于IL3RA抗体的代表性文献摘要：
---
1. **文献名称**：*IL3RA as a biomarker for acute myeloid leukemia diagnosis*
**作者**：Smith, J.R. et al.
**摘要**：该研究通过流式细胞术验证IL3RA(CD123)抗体在急性髓系白血病(AML)患者中的高表达，提出其可作为AML诊断的生物标志物，并与患者预后不良相关。
---
2. **文献名称**：*Targeting IL3RA in blastic plasmacytoid dendritic cell neoplasm*
**作者**：Wang, L. & Frankel, S.R.
**摘要**：探讨抗IL3RA单克隆抗体(如Tagraxofusp)在治疗浆细胞样树突状细胞肿瘤(BPDCN)中的疗效，显示其通过靶向IL3RA介导的细胞凋亡显著改善患者生存率。
---
3. **文献名称**：*IL3RA antibody-drug conjugates for solid tumors*
**作者**：Garcia-Castro, A. et al.
**摘要**：开发新型IL3RA抗体-药物偶联物(ADC)，在实体瘤模型中验证其特异性杀伤IL3RA高表达肿瘤细胞的能力，为靶向治疗提供新策略。
---
注：以上文献为示例，实际引用时需核对真实来源及最新研究进展。
**Background of IL3RA Antibodies**
The interleukin-3 receptor alpha (IL3RA, also known as CD123) is a subunit of the interleukin-3 receptor (IL-3R), a type I cytokine receptor expressed on hematopoietic cells, endothelial cells, and certain cancer cells. IL3RA combines with the beta common subunit (βc, shared with IL-5 and GM-CSF receptors) to form a high-affinity receptor complex. IL-3 binding triggers JAK/STAT, MAPK, and PI3K signaling pathways, regulating cell survival, proliferation, and differentiation, particularly in myeloid lineages.
IL3RA antibodies are tools or therapeutics targeting this subunit. In research, they help study IL-3R expression and signaling in hematopoiesis, immune responses, and diseases like leukemia, where CD123 is often overexpressed in acute myeloid leukemia (AML) and blastic plasmacyid dendritic cell neoplasm (BPDCN). Therapeutically, anti-IL3RA agents include antibody-drug conjugates (e.g., Tagraxofusp) and CAR-T cells designed to target CD123+ malignancies.
Additionally, IL3RA is implicated in autoimmune disorders; its blockade may modulate pathogenic immune cell activity. However, targeting IL3RA carries risks, as it is expressed on healthy hematopoietic stem cells, necessitating careful therapeutic design. Overall, IL3RA antibodies bridge basic research and clinical innovation in oncology and immunology.
×
